The firm’s Polish extraction facility has secured accreditation of its Hazard Analysis and Critical Control Point system from global quality and certification company LL-C Group, as well as confirmation that its operations meet the requirements of Good Manufacturing Practice and Good Hygiene Practice standards for food manufacturing.
The medical cannabis group said this achievement, alongside the recent announcement regarding its Novel Food submission, underpins its commitment to delivering the highest level of regulatory compliance and product quality.
It added that its CBD therapeutics division continues to position itself as a leader in the European and global CBD space, and comprises a seed to consumer integrated supply chain.
The company said it has selected grow partners cultivating the highest quality European seed strain hemp, an extraction facility in Poland producing Novel Food grade bulk wholesale ingredients and finished consumer products, and a UK manufacturing facility.
Sativa Wellness added that it is experiencing increasing demand for its cannabinoid spectrum Distillate bulk ingredients, so it’s boosting the production schedule and processes to increase capacity.
It anticipates strong ongoing demand for bulk ingredients and finished products across the UK and Europe in-light of the European Union’s highest court ruling that CBD is not a narcotic drug, and the Novel Food authorisation process.
“Quality and product safety are paramount within our organisation. Our adherence to these international safety standards assures our customers that we provide them with safe and quality products – CBD you can trust,” said executive chairman Geremy Thomas in a release.
“We welcome the clarity from UK and European authorities that sets out a clear regulatory pathway, that will allow consumers to benefit from un-fettered access to CBD products.”